topotecan/脳卒中

OBJECTIVE To compare outcomes of intra-arterial chemotherapy for retinoblastoma as primary therapy before (Era I) and during (Era II) the intravitreal chemotherapy era. METHODS In this retrospective interventional case series at a tertiary referral center, 66 eyes of 66 patients with untreated

OBJECTIVE To determine the efficacy of rescue intra-arterial chemotherapy (IAC) for retinoblastoma recurrence following failed initial IAC. METHODS Retrospective, non-comparative, interventional case series of 12 eyes in 12 patients. METHODS Rescue IAC employed chemotherapy agents of melphalan (5mg,

OBJECTIVE To report on our 3-year experience with the use of superselective ophthalmic artery infusion of chemotherapy as initial, primary treatment for intraocular retinoblastoma. METHODS Prospective, institutional review board-approved clinical trial. METHODS Twenty-eight eyes of 23 newly

OBJECTIVE The aim of this study is to describe treatment outcomes and complications of selective intra-arterial chemotherapy (IAC) for intraocular retinoblastoma (RB). METHODS A retrospective, interventional series of 10 eyes with RB which underwent IAC using melphalan (5 mg/7.5 mg) and topotecan (1

OBJECTIVE To analyze our 5-year experience of intra-arterial chemotherapy (IAC) for retinoblastoma as primary or secondary therapy. METHODS Retrospective interventional case series. METHODS A total of 70 eyes of 67 patients. METHODS Ophthalmic artery chemotherapy infusion under fluoroscopic guidance